About Armune BioScience
Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing.
Apifiny is a technology that takes advantage of a man’s own immune system which generates autoantibodies against tumor activity in prostate tissue. Such autoantibodies are detectable in a patient’s serum, providing the basis for Armune’s minimally invasive early diagnostic test. It is well known that early detection of cancer will improve long term survival rates, so this technology may potentially have a profound effect on this disease.
ST. CLAIR SHORES, MICH. April 14, 2015 The Michigan Institute of Urology...Read more